Hexarelin + CJC-1295: Maximum GH Release Stack
Hexarelin
Potent GHRP - strongest acute GH release with cardioprotective properties
CJC-1295
GHRH analogue - stimulates pituitary GH synthesis and primes release
The combination of Hexarelin and CJC-1295 represents one of the most potent peptide stacks for growth hormone release. This pairing brings together the strongest GHRP (Hexarelin) with a long-acting GHRH analogue (CJC-1295) to produce GH pulses that may exceed those achieved with other secretagogue combinations.
What distinguishes this stack is Hexarelin's unique dual action: in addition to being the most potent ghrelin receptor agonist for GH release, Hexarelin has demonstrated cardioprotective effects independent of its GH-releasing properties. Research has shown direct protective actions on cardiac tissue through mechanisms including activation of cardiac GHSR-1a receptors and downstream cardioprotective signalling pathways.
This makes the Hexarelin + CJC-1295 combination particularly interesting for research focused on both maximum GH optimization and cardiovascular health. However, this potency comes with trade-offs—Hexarelin causes more cortisol and prolactin elevation than selective alternatives like Ipamorelin, and pituitary desensitisation is a significant consideration with chronic use.
**Critical Disclaimer:** Neither Hexarelin nor CJC-1295 is approved for human therapeutic use by any regulatory authority including the MHRA, EMA, or FDA. Both are prohibited by WADA in sport. This content is for educational and research purposes only. Any use should only occur under qualified medical supervision within appropriate legal frameworks.
Synergistic Mechanism
The Dual-Pathway Synergy with Maximum Potency
How Hexarelin Works (Ghrelin Pathway)
Hexarelin is a synthetic hexapeptide and the most potent growth hormone releasing peptide (GHRP) in its class:
Comparative GH Release Potency:
- Hexarelin > GHRP-6 > GHRP-2 > Ipamorelin
- Produces the largest acute GH pulse of any GHRP
- Effect is dose-dependent up to saturation
Mechanism of Action:
Hexarelin binds to growth hormone secretagogue receptor type 1a (GHS-R1a), the ghrelin receptor, on pituitary somatotrophs. This triggers:
- Rapid release of stored GH from secretory vesicles
- Amplification of GHRH signalling when co-administered
- Reduction of somatostatin's inhibitory tone
- Acute GH pulse within 15-30 minutes of administration
Cardioprotective Mechanisms (Unique to Hexarelin):
Beyond GH release, Hexarelin has direct cardiac effects:
- **GHSR-1a in Heart:** Cardiac tissue expresses ghrelin receptors; Hexarelin binding activates protective pathways
- **Anti-apoptotic Effects:** Reduces cardiac cell death in ischaemia models
- **Anti-fibrotic Properties:** May reduce cardiac fibrosis
- **Coronary Vasodilation:** Improves coronary blood flow
- **Independent of GH:** These effects occur even when GH is blocked
How CJC-1295 Works (GHRH Pathway)
CJC-1295 is a synthetic analogue of growth hormone releasing hormone with enhanced stability:
Mod GRF 1-29 (CJC-1295 without DAC):
- Half-life: ~30 minutes
- Produces physiological pulsatile GH release
- Preferred for combination protocols
CJC-1295 with DAC:
- Half-life: 6-8 days (albumin binding)
- Produces sustained GH elevation
- Less commonly used with Hexarelin
**Mechanism:** CJC-1295 binds to GHRH receptors on pituitary somatotrophs, activating cAMP pathways that:
- Increase GH gene transcription and synthesis
- Prime somatotrophs for secretion
- Maintain pituitary GH stores
- Potentiate response to ghrelin-pathway agonists
The Synergistic Effect
When Hexarelin and CJC-1295 are administered together:
1. **Maximal Receptor Stimulation:** Both GHRH-R and GHS-R are simultaneously activated, producing synergistic rather than merely additive effects
2. **Priming and Release:** CJC-1295 increases GH synthesis and 'primes' the pituitary, while Hexarelin triggers maximum release of stored GH
3. **Enhanced Pulse Amplitude:** The resulting GH pulse may be 10-15x greater than either peptide alone—potentially the highest achievable with peptide secretagogues
4. **Dual Cardiovascular Benefit:** CJC-1295's GH/IGF-1 effects on metabolism combine with Hexarelin's direct cardioprotective actions
Key Difference from Ipamorelin Stacks
Compared to CJC-1295 + Ipamorelin:
- **Greater GH release:** Hexarelin produces larger GH pulses
- **Cardioprotection:** Hexarelin has unique cardiac benefits
- **More side effects:** Cortisol, prolactin, and appetite elevation
- **Desensitisation risk:** Hexarelin causes faster pituitary desensitisation
- **Less selective:** Ipamorelin is the 'cleaner' option for pure GH focus
Research Evidence
Research Evidence
Hexarelin Cardioprotective Research
**Muccioli et al. (1998):** Demonstrated specific binding sites for Hexarelin in cardiac tissue, independent of pituitary GHS-R, suggesting direct cardiac action.
**Bisi et al. (1999):** Showed Hexarelin improved cardiac output in patients with severe GH deficiency, with effects beyond those expected from GH replacement alone.
**Locatelli et al. (1999):** Confirmed Hexarelin's cardioprotective effects in ischaemia-reperfusion injury models, reducing infarct size and cardiac cell death.
**Rossoni et al. (2000-2004):** Series of studies demonstrating Hexarelin's protective effects on isolated rat hearts subjected to ischaemia, showing reduced ventricular arrhythmias and improved post-ischaemic recovery.
**Mao et al. (2014):** Research showed Hexarelin protected against cardiac fibrosis and remodelling in animal models of heart failure.
Hexarelin GH Release Research
**Ghigo et al. (1994):** Early characterisation of Hexarelin showing it was the most potent GHRP tested, with dose-dependent GH release in humans.
**Arvat et al. (1995):** Demonstrated Hexarelin's ability to produce GH release comparable to or exceeding direct GH administration, with synergistic effects when combined with GHRH.
**Rahim et al. (1998):** Showed that chronic Hexarelin administration led to pituitary desensitisation, with reduced GH response over time—an important limitation.
GHRH + GHRP Synergy Research
**Bowers et al. (1990s):** Foundational work establishing that GHRH + GHRP combinations produce GH release 5-10x greater than either alone.
**Veldhuis et al. (2005):** Confirmed the synergistic nature of dual-pathway stimulation in GH secretion, supporting the rationale for combination protocols.
CJC-1295 Research
**Teichman et al. (2006):** Demonstrated CJC-1295's ability to produce sustained IGF-1 elevation with 2-10 fold increase in mean GH concentrations.
Research Limitations
- Most Hexarelin research is preclinical or small-scale human studies
- Specific Hexarelin + CJC-1295 combination studies are limited
- Long-term human safety data is lacking
- Desensitisation protocols not well-defined
- Translation of cardiac benefits to clinical outcomes not established
We do not publish stack protocols
Peptide Authority does not publish doses, reconstitution recipes, injection schedules, or cycle lengths for combinations of unlicensed peptides. This is a deliberate editorial position — we are an evidence and risk-intelligence publisher, not a prescriber. The reasoning is set out in detail in our no dosing, no sourcing policy.
For an honest review of what proponents of this kind of combination claim versus what the published evidence actually supports, see the combination claim-reviews. If you are considering any peptide medicine, speak to a GMC-registered doctor or GPhC-registered pharmacist.
Expected Outcomes
Expected Research Outcomes
Growth Hormone and IGF-1
Acute Effects:
- Large GH pulse within 15-30 minutes
- Peak levels potentially 10-15x baseline
- Duration: 2-4 hours of elevated GH
Chronic Effects:
- Elevated mean 24-hour GH levels
- Increased IGF-1 (typically 20-50% increase)
- Improved GH pulsatility pattern
**Note:** Desensitisation may reduce effects over time
Body Composition
Fat Metabolism:
- Enhanced lipolysis during fasted states
- Potential reduction in visceral fat
- Effects most pronounced with caloric control
Lean Mass:
- May support muscle protein synthesis
- Enhanced recovery from training
- IGF-1 effects on muscle anabolism
Cardiovascular (Based on Hexarelin Research)
Potential Benefits:
- Improved coronary blood flow
- Enhanced cardiac contractility
- Protection against ischaemic damage (theoretical)
- Reduced cardiac fibrosis markers
Important Caveats:
- Human cardiovascular outcome data limited
- Acute effects on heart rate/blood pressure possible
- Not validated as cardiovascular therapy
- Cortisol elevation may counteract some benefits
Sleep and Recovery
Sleep Quality:
- GHRH pathway promotes slow-wave sleep
- Enhanced restorative sleep phases
- Some report vivid dreams
- Better recovery between training sessions
Tissue Repair:
- GH supports connective tissue synthesis
- May accelerate recovery from injury
- Enhanced collagen synthesis
Side Effect Profile
Hexarelin-Related:
- Cortisol elevation (higher than Ipamorelin)
- Prolactin elevation (higher than Ipamorelin)
- Appetite stimulation (moderate, less than GHRP-6)
- Water retention and bloating
- Flushing and warmth post-injection
- Tingling/numbness (temporary)
General GH-Related:
- Joint discomfort (especially at higher doses)
- Carpal tunnel-like symptoms
- Potential glucose metabolism effects
Comparative Positioning
vs. CJC-1295 + Ipamorelin:
- Greater GH release potential
- Unique cardioprotective benefits
- More side effects
- Greater desensitisation risk
- Better for: maximum GH research, cardiac research
- Worse for: clean GH optimization, long-term use
vs. CJC-1295 + GHRP-6:
- Less appetite stimulation
- Better for those not wanting increased hunger
- Stronger cardioprotective evidence
- Similar desensitisation concerns
Safety Considerations
Safety Considerations
Hexarelin-Specific Concerns
Pituitary Desensitisation:
- Most significant limitation of Hexarelin
- GH response diminishes with chronic use
- May require cycling or rotation strategies
- Desensitisation timeline not precisely defined
Hormonal Effects:
- Cortisol elevation: may affect stress response, sleep, metabolism
- Prolactin elevation: potential effects on libido, mood (usually modest)
- Neither approaches therapeutic hormone levels but warrants monitoring
Acute Cardiovascular Effects:
- May cause transient increases in heart rate
- Blood pressure effects possible
- Those with existing cardiovascular conditions require caution
General GH Secretagogue Concerns
Cancer and Tumour Risk:
- Theoretical concern: GH/IGF-1 may promote tumour growth
- Contraindicated in those with active malignancy
- History of cancer requires careful consideration
- Not validated as safe in cancer survivors
Glucose Metabolism:
- GH has anti-insulin effects
- Potential for glucose intolerance with prolonged use
- Diabetics or pre-diabetics require monitoring
- May affect medication requirements
Growth of Existing Structures:
- Potential for enlargement of organs, tissues
- Theoretical concerns about cardiac hypertrophy
- Long-term effects not characterised
Drug Interactions
Potentially Significant:
- Corticosteroids: may affect cortisol-related side effects
- Diabetes medications: GH affects glucose metabolism
- Other hormones: potential interactions with HRT, TRT
- Anti-arrhythmics: Hexarelin's cardiac effects
Unknown Interactions:
- Most drug interactions not studied
- Exercise caution with any concurrent medications
- Disclose all compounds to healthcare providers
Contraindications
Absolute:
- Active malignancy or cancer history
- Pregnancy and breastfeeding
- Children and adolescents (unless under specialist care)
- Uncontrolled diabetes
Relative:
- Cardiovascular disease (despite cardioprotective evidence, acute effects warrant caution)
- Hypertension
- History of pituitary disorders
- Significant hepatic or renal impairment
- Concurrent use of other hormonal therapies
Regulatory and Legal Status
- Not approved for any therapeutic use
- Classified as research chemicals only
- Prohibited by WADA in all sports
- Legal status varies by jurisdiction
- Quality and purity unregulated
Monitoring Recommendations
Baseline (Theoretical):
- Fasting glucose and HbA1c
- IGF-1 levels
- Lipid panel
- Liver and kidney function
- Cardiac evaluation if history present
Ongoing:
- Periodic IGF-1 monitoring
- Glucose monitoring, especially early in use
- Assessment for side effects
- Cardiac symptoms monitoring
Frequently Asked Questions
Conclusion
Conclusion
The Hexarelin + CJC-1295 combination represents the most potent peptide stack for growth hormone release, bringing together the strongest GHRP with a proven GHRH analogue. What makes this pairing particularly interesting is Hexarelin's unique dual action—combining maximum GH secretion with direct cardioprotective effects independent of growth hormone.
Key Strengths:
- Produces the largest GH pulses achievable with peptide secretagogues
- Hexarelin's cardioprotective properties offer potential cardiovascular benefits
- Synergistic dual-pathway activation maximises pituitary response
- May support body composition, recovery, and tissue repair research
Key Limitations:
- Pituitary desensitisation with chronic use limits sustainability
- Cortisol and prolactin elevation higher than selective alternatives
- Less suitable for fat loss or calorie-restricted protocols
- Limited long-term human safety data
- Neither peptide approved for therapeutic use
This stack is best suited for research focused on maximum GH release or cardiovascular protection, rather than general-purpose GH optimization. For most users seeking sustainable GH enhancement with minimal side effects, the CJC-1295 + Ipamorelin combination offers a cleaner, more practical option.
Anyone exploring these peptides should work with qualified healthcare providers within appropriate legal frameworks. The research is promising, but translation to validated human therapeutic use has not been established.
Always consult accredited suppliers and qualified healthcare professionals in your jurisdiction.